Effectiveness Of Liposomal Bupivacaine Stellate Ganglion Blockade In Preventing Atrial Fibrillation After Isolated Coronary Artery Bypass Grafting Surgery: A Randomized Placebo-Controlled Trial
Mayo Clinic
Summary
The purpose of this study is assess the incidence of postoperative atrial fibrillation (POAF) within one week of surgery in patients who receive pre-surgical stellate ganglion blockade with liposomal bupivacaine, compared to those receiving a saline placebo, using continuous electrocardiographic monitoring via wearable ECG devices.
Eligibility
- Age range
- 40+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Adults aged ≥40 years scheduled to undergo isolated coronary artery bypass grafting will be eligible. * Cases will also remain eligible if, after the initial surgical listing, additional procedures-such as valvular interventions or septal myectomy-are performed, OR if coronary artery bypass grafting (CABG) is listed as the primary intervention with other procedures noted as possible additional interventions. * Cases will also remain eligible if additional procedures-such as left atrial appendage ligation, MAZE procedure, cryotherapy, or pulmonary vein isolation-are conco…
Interventions
- DrugLiposomal bupivacaine
Patients undergoing isolated coronary artery bypass grafting will receive a stellate ganglion block using liposomal bupivacaine prior to surgery
- DrugPlacebo
Patients undergoing isolated coronary artery bypass grafting will receive a saline placebo injection to the stellate ganglion prior to surgery
Location
- Mayo Clinic in RochesterRochester, Minnesota